2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD19

CD19

CD19 is a 95 kD transmembrane glycoprotein that is highly expressed in human B cells and certain types of tumors, belonging to the immunoglobulin superfamily. CD19 plays a crucial role in regulating the threshold of B cell signaling by modulating both B cell receptor (BCR)-dependent and independent signaling pathways, thereby playing an essential role in the initiation of immune responses and the maintenance of tolerance. CD19 typically forms a multimolecular complex with molecules like CD21 and CD81 on the surface of mature B cells, where it exerts its dominant signaling function.
CD19 works in cooperation with the BCR to promote the activation of Src family protein tyrosine kinases, enhancing B cell proliferation and expansion. It can also independently enhance B cell activation by binding to the complement receptor CD21. Mice and humans lacking CD19 show weakened T cell-dependent immune responses and low levels of immunoglobulins, leading to immune dysfunction. High expression of CD19 is closely associated with B cell lymphoma, acute lymphoblastic leukemia (ALL), and other malignancies. CD19 monoclonal antibodies are used in the study of B cell malignancies[1].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9963
    Blinatumomab
    		Inhibitor 98.78%
    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.
    Blinatumomab
  • HY-P99113
    Inebilizumab
    		Inhibitor 99.00%
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
    Inebilizumab
  • HY-P991028
    Surovatamig
    		Inhibitor 99.89%
    Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.
    Surovatamig
  • HY-P99711
    Loncastuximab
    		Inhibitor ≥99.0%
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).
    Loncastuximab
  • HY-P99761
    Obexelimab
    		Inhibitor 99.99%
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.
    Obexelimab
  • HY-P991898
    IASO-782
    		Inhibitor
    IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
    IASO-782
  • HY-P991899
    IKS03 Antibody
    IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
    IKS03 Antibody
  • HY-P991897
    Anti-CD19 Antibody (hA19)
    Anti-CD19 Antibody (hA19) is an antibody against human CD19. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD19 Antibody (hA19)
  • HY-P99868
    Duvortuxizumab
    		≥99.0%
    Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E.
    Duvortuxizumab
  • HY-P99113A
    Inebilizumab (FUT8-KO)
    Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica.
    Inebilizumab (FUT8-KO)
  • HY-P99976
    Anti-Mouse CD19 Antibody (1D3)
    		Inhibitor 98.778%
    Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells.
    Anti-Mouse CD19 Antibody (1D3)
  • HY-153084A
    CD19 CAR mRNA (Human)
    CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
    CD19 CAR mRNA (Human)
  • HY-P99285
    Denintuzumab
    		Inhibitor ≥99.0%
    Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.
    Denintuzumab
  • HY-P990017
    Englumafusp alfa
    		Inhibitor 99.93%
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells.
    Englumafusp alfa
  • HY-P990694
    Zeripatamig
    		≥99.0%
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Zeripatamig
  • HY-P99914
    Emfizatamab
    Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.
    Emfizatamab
  • HY-P990729
    Budoprutug
    Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Budoprutug
  • HY-P990870
    Anti-CD19 Antibody (4G7)
    		Inhibitor 98%
    Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD19 Antibody (4G7)
  • HY-P990571
    Coltuximab
    		Inhibitor 98.43%
    Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a molecular weight (MW) of 144.70 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Coltuximab
  • HY-P991176
    RG-6333
    		Agonist 98.05%
    RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
    RG-6333
Cat. No. Product Name / Synonyms Application Reactivity